EA202090731A1 - Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка - Google Patents

Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка

Info

Publication number
EA202090731A1
EA202090731A1 EA202090731A EA202090731A EA202090731A1 EA 202090731 A1 EA202090731 A1 EA 202090731A1 EA 202090731 A EA202090731 A EA 202090731A EA 202090731 A EA202090731 A EA 202090731A EA 202090731 A1 EA202090731 A1 EA 202090731A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protein
composition
therapeutic protein
pharmaceutical composition
lyophilized pharmaceutical
Prior art date
Application number
EA202090731A
Other languages
English (en)
Inventor
Клеа Талли
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63686145&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202090731(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA202090731A1 publication Critical patent/EA202090731A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к способу получения лиофилизированного фармацевтического состава на основе терапевтического белка, который включает (a) получение состава с нерасфасованным количеством терапевтического белка, (b) измерение концентрации терапевтического белка в указанном нерасфасованном составе, (c) корректировку заполняемой массы белка в указанном нерасфасованном составе с получением фиксированной дозы белка и (d) лиофилизацию состава со скорректированной заполняемой массой белка с получением конечного состава в контейнере, где концентрация продукта после восстановления с помощью фиксированного объема находится в пределах предварительно определенного диапазона приемлемых значений. Данный способ является особенно подходящим для составов с низкими концентрациями белка (например, от 0,05 до 20 мг/мл).
EA202090731A 2017-09-15 2018-09-10 Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка EA202090731A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762559420P 2017-09-15 2017-09-15
PCT/US2018/050305 WO2019055357A1 (en) 2017-09-15 2018-09-10 METHOD FOR THE LYOPHILIZED PHARMACEUTICAL FORMULATION OF A THERAPEUTIC PROTEIN

Publications (1)

Publication Number Publication Date
EA202090731A1 true EA202090731A1 (ru) 2020-06-11

Family

ID=63686145

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090731A EA202090731A1 (ru) 2017-09-15 2018-09-10 Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка

Country Status (22)

Country Link
US (2) US20210369616A1 (ru)
EP (1) EP3681483B1 (ru)
JP (2) JP2020534255A (ru)
KR (1) KR20200054251A (ru)
CN (1) CN111148510A (ru)
AU (1) AU2018334502A1 (ru)
BR (1) BR112020004902A2 (ru)
CA (1) CA3072600A1 (ru)
CL (1) CL2020000625A1 (ru)
DK (1) DK3681483T3 (ru)
EA (1) EA202090731A1 (ru)
ES (1) ES2925232T3 (ru)
HU (1) HUE059339T2 (ru)
IL (2) IL272513B2 (ru)
LT (1) LT3681483T (ru)
MA (1) MA50239A (ru)
MX (1) MX2020002896A (ru)
PL (1) PL3681483T3 (ru)
PT (1) PT3681483T (ru)
SG (1) SG11202001449VA (ru)
SI (1) SI3681483T1 (ru)
WO (1) WO2019055357A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111595658B (zh) * 2020-06-06 2023-11-14 宾傲 一种提取细胞中蛋白的裂解液及其制备方法
US11583521B2 (en) * 2020-07-01 2023-02-21 Jubilant Pharma Holdings Inc. Long-acting injection dosage form of beta 3 adrenoreceptor agonists
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
CN113087782B (zh) * 2021-04-09 2021-12-14 北京美联泰科生物技术有限公司 一种中枢神经特异性蛋白的冻干方法
BR112023024757A2 (pt) * 2021-06-01 2024-02-15 Amgen Inc Método acelerado de preparação de formulações de proteínas liofilizadas
WO2023180525A1 (en) * 2022-03-24 2023-09-28 Richter Gedeon Nyrt. Method for the manufacture of biopharmaceuticals
CN115932239B (zh) * 2022-12-22 2024-02-20 广州市进德生物科技有限公司 一种氧化低密度脂蛋白保护剂、测定氧化低密度脂蛋白的检测试剂盒及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
WO1999054440A1 (en) 1998-04-21 1999-10-28 Micromet Gesellschaft Für Biomedizinische Forschung Mbh CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
EP1455822A4 (en) 2001-11-09 2004-12-29 Centocor Inc LYOPHILIZED MONOCLONAL ANTIBODY COMPOSITIONS
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
WO2008143867A1 (en) 2007-05-15 2008-11-27 Stryker Corporation Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20130273055A1 (en) * 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US10017441B2 (en) * 2013-05-02 2018-07-10 The University Of North Carolina At Chapel Hill Direct anti-markovnikov addition of acids to alkenes
EP3125923A4 (en) * 2014-03-29 2017-12-06 Intas Pharmaceuticals Limited Lyophilized pharmaceutical composition of fc-peptide fusion protein
TWI797073B (zh) * 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物

Also Published As

Publication number Publication date
MX2020002896A (es) 2020-07-22
US20190083402A1 (en) 2019-03-21
IL272513B2 (en) 2023-04-01
US20210369616A1 (en) 2021-12-02
BR112020004902A2 (pt) 2020-09-15
IL297824A (en) 2023-01-01
CL2020000625A1 (es) 2020-08-21
IL272513B (en) 2022-12-01
DK3681483T3 (da) 2022-08-29
CA3072600A1 (en) 2019-03-21
ES2925232T3 (es) 2022-10-14
JP2020534255A (ja) 2020-11-26
MA50239A (fr) 2020-07-22
EP3681483B1 (en) 2022-05-18
JP2023126930A (ja) 2023-09-12
SG11202001449VA (en) 2020-03-30
WO2019055357A1 (en) 2019-03-21
IL272513A (en) 2020-03-31
PL3681483T3 (pl) 2022-09-26
PT3681483T (pt) 2022-08-22
LT3681483T (lt) 2022-09-12
CN111148510A (zh) 2020-05-12
HUE059339T2 (hu) 2022-11-28
AU2018334502A1 (en) 2020-03-12
EP3681483A1 (en) 2020-07-22
KR20200054251A (ko) 2020-05-19
SI3681483T1 (sl) 2022-10-28

Similar Documents

Publication Publication Date Title
EA202090731A1 (ru) Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка
PH12017500844A1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
MX347504B (es) Formulaciones concentradas de proteina y usos de las mismas.
EA201691790A1 (ru) Способ получения продукта глатирамера ацетата
NZ711567A (en) Antibody formulations
MX2021005085A (es) Formulacion de anticuerpo.
NZ702342A (en) Pharmaceutical formulation
PH12016500414B1 (en) Solid preparation containing choline alfoscerate and method for preparing same
MX2021012939A (es) Formulaciones de factor ix liofilizadas.
CO2021007830A2 (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
RU2016144190A (ru) Стабильные белковые препараты, содержащие молярный избыток сорбитола
MX2017012312A (es) Formulacion estable para administracion parenteral de tapentadol.
RU2019111152A (ru) Новый способ стабилизации биофармацевтического лекарственного продукта при производстве
MX2021007047A (es) Formulaciones de anticuerpos.
GB201122430D0 (en) Reconstitution method for high concentration dry protein formulation
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
EA201100682A1 (ru) Стабильная фармацевтическая композиция, содержащая прегабалин, капсула, ее содержащая, способ получения и применение
RU161522U1 (ru) Способ снижения болевой чувствительности животного
EA201800360A1 (ru) Способ получения фармацевтической композиции, содержащей бендамустин, фармацевтическая композиция бендамустина
EA201800229A1 (ru) Способ получения пеметрекседа динатрия 2,5-гидрата и фармацевтическая композиция, содержащая пеметрекседа динатрия 2,5-гидрат
MX2022000625A (es) Composicion farmaceutica de temozolomida.
AR112343A1 (es) Composiciones de anticuerpos estabilizadas y métodos para producirlas
PL417625A1 (pl) Sposób wytwarzania kapsułek metanosulfonianu imatinibu
MX2019003257A (es) Formulacion estable para la administracion parenteral de tapentadol.